tetano
Editor, Senior Moderator
Case Rep Nephrol Dial
. 2022 Nov 22;12(3):234-237.
doi: 10.1159/000525737. eCollection 2022 Sep-Dec.
Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases
Craig Peter Coorey[SUP] 1 2 [/SUP], Elaine Phua[SUP] 1 [/SUP], Angela Chou[SUP] 3 [/SUP], Yvonne Shen[SUP] 1 [/SUP], Amanda Mather[SUP] 1 [/SUP]
Affiliations
Abstract
There have been reports of rare de novo glomerular diseases following vaccination for coronavirus disease 2019 (COVID-19). We report two cases of anti-glomerular basement membrane (GBM) disease in previously healthy females after Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19). The first case was a 69-year-old female who developed lethargy and anuria approximately 8 weeks after her first dose of Oxford-AstraZeneca COVID-19 vaccine. The second case was a 72-year-old female who developed malaise and diarrhoea approximately 3 weeks after her second dose of Oxford-AstraZeneca COVID-19 vaccine. Both cases had severe acute kidney injury, raised anti-GBM antibody titres, and renal biopsies consistent with anti-GBM disease. Both cases were commenced on haemodialysis and treated with high dose glucocorticoids, cyclophosphamide, and plasmapheresis. Neither patient had recovery of renal function, and both remain dialysis dependent. These cases add to the previously reported cases of anti-GBM disease after mRNA COVID-19 vaccination. As more COVID-19 vaccinations are administered worldwide, it would be important for clinicians to be aware of this possible association, and continued surveillance is warranted.
Keywords: Acute kidney injury; Glomerular disease; Glomerulonephritis.
. 2022 Nov 22;12(3):234-237.
doi: 10.1159/000525737. eCollection 2022 Sep-Dec.
Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases
Craig Peter Coorey[SUP] 1 2 [/SUP], Elaine Phua[SUP] 1 [/SUP], Angela Chou[SUP] 3 [/SUP], Yvonne Shen[SUP] 1 [/SUP], Amanda Mather[SUP] 1 [/SUP]
Affiliations
- PMID: 36465571
- PMCID: PMC9710461
- DOI: 10.1159/000525737
Abstract
There have been reports of rare de novo glomerular diseases following vaccination for coronavirus disease 2019 (COVID-19). We report two cases of anti-glomerular basement membrane (GBM) disease in previously healthy females after Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19). The first case was a 69-year-old female who developed lethargy and anuria approximately 8 weeks after her first dose of Oxford-AstraZeneca COVID-19 vaccine. The second case was a 72-year-old female who developed malaise and diarrhoea approximately 3 weeks after her second dose of Oxford-AstraZeneca COVID-19 vaccine. Both cases had severe acute kidney injury, raised anti-GBM antibody titres, and renal biopsies consistent with anti-GBM disease. Both cases were commenced on haemodialysis and treated with high dose glucocorticoids, cyclophosphamide, and plasmapheresis. Neither patient had recovery of renal function, and both remain dialysis dependent. These cases add to the previously reported cases of anti-GBM disease after mRNA COVID-19 vaccination. As more COVID-19 vaccinations are administered worldwide, it would be important for clinicians to be aware of this possible association, and continued surveillance is warranted.
Keywords: Acute kidney injury; Glomerular disease; Glomerulonephritis.